Hempyre Holdings Ltd. Launches Global Platform for Branded Hemp-Formulated Consumer Packaged Goods
28.4.2020 13:00:00 EEST | Business Wire | Press release
Hempyre Holdings Ltd. (“Hempyre” or the “Company”) is pleased to announce the launch of a global distribution platform of branded hemp-formulated consumer packaged goods focused on beauty, beverage, and wellness.
Headquartered in London, Hempyre has agreed to acquire CMLM Holdings, Inc., dba QIND, a U.S.-based provider of hemp-formulated wellness and beauty products featuring CBD and CBG. Hempyre has also agreed to acquire select beverage and topical brands in the United Kingdom and China and has actively been hiring local executive talent.
Hempyre’s management team is led by Mr. Shannon Soqui, Chief Executive Officer, and Mr. Jason Roth, Chief Strategy Officer. Mr. Soqui was formerly the Chief Executive Officer of QIND, and Mr. Roth was the Co-Founder, Chairman, and Chief Executive Officer of Mile High Labs until October 2019.
Mr. Soqui has 25 years of experience advising and financing emerging growth companies in disruptive markets, including retail and consumer packaged goods. Mr. Soqui has worked exclusively in the cannabis and hemp industry since 2014, after a successful 25-year career in Silicon Valley as an investment banker with firms such as Credit Suisse and UBS, a securities lawyer with Brobeck, Phleger & Harrison, and a CPA with KPMG.
“As hemp becomes legal in more countries, we see a tremendous opportunity for a branded consumer packaged goods platform focused on beauty, beverages, and wellness in selected markets,” said Mr. Soqui. “With a focus on high quality products that are legally compliant, tested and safe, and developing a broad global distribution platform, both wholesale and online, we believe that we will be well positioned to develop brand recognition globally.”
Mr. Roth has 25 years of experience owning consumer packaged goods and medical device companies that have operated internationally, and is respected for his strategic leadership and disciplined approach to driving revenue.
“The European beverage market has very attractive business and financial dynamics given the recent legalization of hemp-infused beverages in the United Kingdom and other parts of Europe,” said Mr. Roth. “Asia is also a very attractive market for us. Our partnerships with major distribution partners and key opinion leaders will enable us to reach hundreds of millions of consumers very effectively.”
About Hempyre
Hempyre is an emerging global provider of branded hemp-formulated consumer packaged goods focused on Beauty, Beverage, and Wellness. Hempyre’s Beauty product line focuses on consumer hemp-formulated topical solutions to protect and rejuvenate their skin and body. Hempyre’s Beverage product line focuses on consumers who are looking for healthy ways in which to consume hemp-formulated distilled alcoholic and non-alcoholic spirits, sparkling and live sodas, pressed juices, water, and other ready-to-drink offerings. Hempyre’s Wellness product line focuses on consumers looking for hemp-derived CBD and CBG alternatives to treat anxiety, inflammation, insomnia, pain, or to manage and regulate their overall health.
Hempyre’s core strategy focuses on product branding and distribution in Europe, China, the U.S., and the Asia-Pacific region, while outsourcing most aspects of raw material production and finished goods manufacturing. Hempyre currently has 11 brands with more than 150 product SKUs across its three product segments. Hempyre’s hemp-formulated products are non-psychoactive and are made from high quality strains of hemp oil extracts containing either pure CBD or CBG, or combined with a broad or full spectrum of hemp compounds, including other cannabinoids and terpenes.
Hempyre’s primary operating subsidiaries are located in London, England, and Portland, Oregon, with additional staff in Hong Kong, and Auckland, New Zealand. With its licenses and permits, and given the emerging legalization of hemp-formulated products, Hempyre exports selected hemp-formulated CBD and CBG products from the U.S. to selected developed countries globally. Hempyre’s U.S. operations are licensed as a hemp handler by the Oregon Department of Agriculture, and act as a base for distribution throughout the U.S., with shipment enabled by the USPS. For raw material production and finished goods manufacturing, Hempyre’s strategy is to rely on farmers and concentrate processors in the U.S. for raw materials, and GMP-certified co-packers and white-label manufacturers for finished goods assembly or production. Hempyre’s hemp-formulated CBD and CBG products are distributed through its global network of distributors and wholesalers, its own and third-party owned e-commerce websites, Company-leased storefronts, and a variety of brick and mortar mainstream retailers. For more information visit www.hempyre.com.
Strategic Opportunities:
Hempyre is interested in discussing potential acquisitions of branded product and/or distribution companies in the Beauty, Beverage, or Wellness segments that could infuse CBD and CBG into their products.
Please contact jason@hempyre.com for information.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200428005331/en/
Contact information
U.S. Media Contact:
Mr. Erik Ritchie
media@hempyre.com
888-743-6797
U.K. Media Contact:
Mr. William Draper
media@hempyre.com
+44 (0) 800 020 9806
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 12:48:00 EEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
